Beijing Tide Pharmaceutical Co. Ltd. has patented new cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of bronchiectasis.
Offering $2.2 billion for Rapt Therapeutics Inc. and gaining its long-acting lead drug, ozureprubart, for food allergy and other indications, GSK plc is positioning itself to compete with market leader Xolair (omalizumab), developed by Roche AG’s Genentech unit and Novartis AG.
The range of effects caused by rhinoviruses – the pathogens responsible for the common cold – motivated scientists at Yale University to study the human nasal epithelium and uncover a previously undescribed defense mechanism. The interferon-mediated protective response in these cells can limit infection, whereas a maladaptive response tends to worsen it. Based on these findings, the researchers have identified potential therapeutic targets to reduce inflammation associated with rhinovirus infection.
Pulmonary fibrosis is a chronic, progressive respiratory disease in which the normal barrier between alveoli and capillaries is compromised, leading to persistent injury and inflammation of the lung epithelium.
After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its lead candidate, RB-042, an inhaled splice-switching oligonucleotide for treating chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases.
Animate Biosciences Inc. has released promising preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeutic peptides significantly reduced lung fibrosis and inflammation.
Asthma is an inflammatory airway disease characterized by shortness of breath and wheezing, among others, with a varying global prevalence of 1%-18%. Both airway hyperresponsiveness and airway remodeling are two important features of the disease, where epithelial-mesenchymal transition (EMT) plays a critical role. Glucocorticoid induced 1 (GLCCI1) is a protein involved in glucocorticoid signaling that has gained interest in the field of asthma, where it has been shown to be downregulated in the lung tissues of mice with asthma and its overexpression has been found to alleviate airway remodeling.
Tianjin Tianyao Pharmaceuticals Co. Ltd. has identified glucocorticoid receptor (GR) agonists reported to be useful for the treatment of conjunctivitis, asthma, chronic obstructive pulmonary disease, allergic rhinitis, nasal polyps, Crohn’s disease, eczema and psoriasis.
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official disclosure of some billion-dollar collaborations, leading with Abbvie Inc.’s exclusive licensing deal with Remegen Co. Ltd. for PD-1/VEGF-targeted bispecific antibody RC-148.
After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its lead candidate, RB-042, an inhaled splice-switching oligonucleotide for treating chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases.
RSS
